Startups

These startups are repping Philly’s biotech community at a national competition

OncopHore Nanotechnologies, CeraScript Diagnostics and GlioLink, Inc. are in the final stages of the Freedom from Cancer Startup Challenge in Maryland.

Biotech lab hijinks. (Photo by Flickr user Steve Jurvetson, used under a Creative Commons license)

A competition of startups-to-be offers some insight into Philly’s biotech chops: three Philly-based companies made it to the final stages of the Freedom from Cancer Startup Challenge alongside some 50 companies from around the world.

The business plan face-off, created by Bethesda, Md.-based nonprofit Center for Advancing Innovation (CAI), is an open innovation challenge that seeks to spur, over time, 100 potential startups to join the fight against cancer. It will look to deliver on its goal through the commercialization of existing technologies at government institutions and universities.

Winners will have access to a training program, a small seed investment and access to legal counsel for the technology licensing process. Funding for the competition was provided by the Laura and John Arnold Foundation and MedImmune.

“CAI is poised to create a new paradigm and platform to drive the commercialization of cancer research into medicines that could make a significant impact on the quality of life of cancer patients and their families, reduce the economic burden of exorbitant cancer treatment costs, and perhaps free the world from cancer,” said CAI founder Rosemarie Truman.

Two of the three Philly pitches came from the same duo of postdoctoral researchers: postdoctoral researches Mukta Asnani and Margalit Haber.

Here are the Philly pitches in the final stages of the competition, which will announce its winners at the end of the month:

OncopHore Nanotechnologies

  • Makers of a pH-sensitive nanoparticle

CeraScript Diagnostics:

  • Makers of a diagnostics tool for HPV/cervical cancer

https://www.youtube.com/watch?v=CgP21mBFwPw

GlioLink, Inc.

  • A platform for engineering CAR T-cells, by Jefferson postdoctoral researcher Mukesh Kumar

Before you go...

Please consider supporting Technical.ly to keep our independent journalism strong. Unlike most business-focused media outlets, we don’t have a paywall. Instead, we count on your personal and organizational support.

3 ways to support our work:
  • Contribute to the Journalism Fund. Charitable giving ensures our information remains free and accessible for residents to discover workforce programs and entrepreneurship pathways. This includes philanthropic grants and individual tax-deductible donations from readers like you.
  • Use our Preferred Partners. Our directory of vetted providers offers high-quality recommendations for services our readers need, and each referral supports our journalism.
  • Use our services. If you need entrepreneurs and tech leaders to buy your services, are seeking technologists to hire or want more professionals to know about your ecosystem, Technical.ly has the biggest and most engaged audience in the mid-Atlantic. We help companies tell their stories and answer big questions to meet and serve our community.
The journalism fund Preferred partners Our services
Engagement

Join our growing Slack community

Join 5,000 tech professionals and entrepreneurs in our community Slack today!

Trending

19 tech and entrepreneurship events to check out before the holidays

Are digital navigators the answer to closing Philadelphia’s tech gap?

EDA officials are ‘hopeful’ Tech Hubs program will live on under Trump

AI is being used in more and more of the hiring process, especially at high-volume companies

Technically Media